Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are individual-specific. Referenced Program Statement versions within this guideline are for informational purposes only. Please refer to the most current versions of any referenced Program Statement(s). Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp
ABOUT THIS DOCUMENT

This document contains an OVERVIEW AND KEY PRINCIPLES, followed by 13 separate TOPICS related to Antimicrobial Stewardship. This guidance is newly designed so that the topics can be consulted separately or together. The topics are listed as clickable links on the next page. For details on what a particular topic covers, see the short table of CONTENTS at the beginning of that section.

PRINTING: Most likely, you are viewing this document in PDF format. To print an individual topic without printing the entire document, use the page numbers listed below.

<table>
<thead>
<tr>
<th>TO PRINT THIS TOPIC IN THE PDF VERSION...</th>
<th>PRINT PAGES...</th>
<th>TO PRINT THIS TOPIC IN THE PDF VERSION...</th>
<th>PRINT PAGES...</th>
</tr>
</thead>
</table>

WHAT'S NEW IN THIS GUIDANCE?

In this revision of the BOP guidance on Antimicrobial Stewardship, DIAGNOSIS and TREATMENT for each topic are now combined in one section. Other changes include the following:

- **ACUTE RHINOSINUSITIS**: New treatment algorithm.
- **PHARYNGITIS**: Updated information.
- **ACUTE BRONCHITIS**: New treatment algorithm.
- **PNEUMONIA**: Treatment algorithms for HAP, VAP, and HCAP were removed. The CAP algorithm for severe pneumonia references the Infectious Diseases Society of America (IDSA) guidelines, instead of making specific recommendations.
- **OTITIS MEDIA**: New section.
- **SKIN AND SOFT TISSUE INFECTIONS**: Now covered in two updated sections—purulent (including MRSA) and non-purulent (including CELLULITIS). The information on MRSA had previously been covered in a separate set of BOP clinical guidelines, last issued in 2012.
- **CLOSTRIDIUM DIFFICILE INFECTION**: New treatment table.
- **PROBIOTICS**: New section.
- **URINARY TRACT INFECTIONS**: New section.
- **HELICOBACTER PYLORI**: New section.
- **SURGICAL SITE INFECTION PROPHYLAXIS**: New section.
Click on any of the following topics to go to that chapter. Note that each chapter starts on its own page 1.

1. Overview and Key Principles
2. Acute Rhinosinusitis
3. Pharyngitis
4. Acute Bronchitis
5. Pneumonia
6. Otitis Media
7. Purulent Skin and Soft Tissue Infections (SSTIs), Including MRSA
8. Non-Purulent Skin and Soft Tissue Infections (SSTIs)
9. Clostridium difficile Infection
10. Probiotics
11. Urinary Tract Infections
12. Helicobacter pylori
13. Dental Infection
14. Surgical Site Infection Prophylaxis
1. Overview and Key Principles

Contents

A. Goals of the BOP Antimicrobial Stewardship Program ................................................................. 1
B. CDC Core Elements of Antimicrobial Stewardship ................................................................. 2
C. Key Components of Antimicrobial Stewardship .......................................................................... 2
D. Interventions to Improve Antimicrobial Prescribing ................................................................. 3
   Streamlining ................................................................................................................................. 3
   IV to PO Conversion ..................................................................................................................... 3
   General Interventions ................................................................................................................. 4
E. Development of a Local Antimicrobial Stewardship Team ....................................................... 4
F. Educational Resources ................................................................................................................. 4

Antimicrobial resistance is a significant problem throughout the world—leading to increased morbidity, mortality, and healthcare costs. The Centers for Disease Control and Prevention (CDC) states that antibiotic resistance is one of the world’s most pressing public health problems. The CDC estimates that over 2 million illnesses and 23,000 deaths in the U.S. are caused by resistant bacteria each year.1

The growth of resistant microbes is largely due to inappropriate antimicrobial prescribing practices. Studies have shown antibiotic use is unnecessary or inappropriate in as many as 50% of the cases in the United States. Common prescribing concerns include unnecessary antimicrobials, overuse of broad spectrum antibiotics, ineffective agents, wrong doses, and extended durations of therapy.

To combat these circumstances, the BOP Antimicrobial Stewardship Program has been developed. This program relies upon a common centralized approach that is augmented by local institution efforts.

A. Goals of the BOP Antimicrobial Stewardship Program

1. Improve patient outcomes.
2. Decrease antimicrobial resistance.
3. Decrease unnecessary antibiotic use.
4. Decrease unintentional antimicrobial adverse effect.

1 https://www.cdc.gov/drugresistance/about.html
B. CDC Core Elements of Antimicrobial Stewardship\textsuperscript{2, 3}

- Leadership commitment
- Accountability
- Drug expertise
- Action
- Tracking
- Reporting
- Education

C. Key Components of Antimicrobial Stewardship

1. **Education:** Recommended topics should address the appropriate use of antibiotics (e.g., antibiotics used for bacterial infections, but not viral infections; many colds do not require antibiotics; risk of overuse, etc.). Topics can include, but are not limited to, current clinical practice guidelines, drug utilization reviews, current diagnostic methods, peer review findings, risks of antibiotic use, and drug information.

   *Education is recommended for all stakeholders in the healthcare system, including:*
   - Prescribers
   - Staff who administer or distribute medications
   - Patients
   - Executive Staff
   - Department Heads
   - Non-medical staff

   \textit{See Educational Resources below.}

2. **Formulary Management:** The BOP utilizes a formulary with varying degrees of restrictions. Medications are either \textit{unrestricted} (e.g., amoxicillin) or \textit{restricted} (e.g., clarithromycin as a second-line agent requiring physician co-sign). Additionally, some medications may be restricted to use for certain diagnoses.

   Depending upon local circumstances, the pharmacy and therapeutics (P&T) committees in some institutions may choose to place additional restrictions on BOP National Formulary medications or to remove certain items from their local formularies. Restrictions on a formulary medication may include limited duration of use, use limited to certain diagnoses, removal from the formulary based on local resistance patterns, or \textit{local prior approval} (see below).

3. **Local Prior Approval:** As part of \textit{formulary management}, the P&T committee in some institutions may require that the use of certain formulary medications require approval from the institution’s clinical director or pharmacist, or both. Local prior approval, when used, is often applied to second-line therapy and may require culture and sensitivity data.

\textsuperscript{2} Sanchez GV, Fleming-Dutra KE, Roberts RM, Hicks LA. Core Elements of Outpatient Antibiotic Stewardship. \textit{MMWR Recomm Rep.} 2016;65(No. RR-6):1–12. Available at: \url{http://dx.doi.org/10.15585/mmwr.rr6506a1}.

\textsuperscript{3} CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; updated February 23, 2017. Available at: \url{https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html}. 
D. Interventions to Improve Antimicrobial Prescribing

- De-escalation: Convert empiric therapy to narrow therapy (see Streamlining below).
- Dose optimization: Adjust dosing for renal insufficiency, hepatic insufficiency, body weight, etc.
- Converting IV to PO (see IV to PO below).
- Automatic Stop Orders, with mandatory reassessment in 48–72 hours: Reassess the patient once cultures/sensitivities come back; assess whether the patient is improving on the current regimen.
- Alerts for duplicate therapy.
- Distribution of antibiograms, if available.
- Analysis of antimicrobial resistance rates, if available.
- Surveillance of antimicrobial usage.
- Conducting prescribing audits, with feedback to individual prescribers.

*Note:* When determining specific dosing of medications, providers should consider if alternate medication selection or dosing adjustment is necessary due to unrelated conditions (i.e., pregnancy, hepatic disease, renal disease, etc.).

**STREAMLINING**

Streamlining refers to the practice of converting a patient from broad-spectrum to narrow-spectrum antimicrobial therapy. If a provider starts a patient on empiric treatment with broad-spectrum antimicrobials, narrowing the treatment selection is recommended to better meet the patient’s specific needs once culture and sensitivity data are available. This may involve changing antibiotics, reducing the number of medications, or discontinuing treatment.

*Benefits associated with streamlining include:*
- Reduced secondary infections
- Decreased morbidity and mortality
- Minimized antimicrobial resistance
- Minimized toxicity and adverse effects
- Reduced healthcare expenses

**IV TO PO CONVERSION**

The IV to PO conversion promotes many positive clinical outcomes, including:
- Increased quality of life
- Decreased risk of the adverse events associated with IV infusions
- Decreased administration errors, due to the ease of PO administration
- Decreased risk of the secondary infections related to IV catheters
- Hastened discharge for patients in inpatient beds
- Decreased costs related to medications
- Decreased laboratory monitoring
- Decreased personnel time for preparation and administration
GENERAL INTERVENTIONS

- Recommend pharmacy, lab, and quality improvement staff prepare and submit annual reports to the P&T committee that include general antibiotic usage data, antibiograms, and review of prescriber usage.
- Recommend quality improvement and health services staff should review, disseminate, and provide training on infection prevention protocols, including hand-washing, catheter, and other protocols meant to reduce the risk of infection.

E. Development of a Local Antimicrobial Stewardship Team

It is recommended that each institution develop an Antimicrobial Stewardship Team. This is particularly important for all Care Level 3 and Care Level 4 institutions.

Recommended members of the team include:
- Advanced practice practitioner
- Infection prevention and control specialist
- Laboratory personnel
- Nurse
- Pharmacist
- Physician

F. Educational Resources

- Centers for Disease Control and Prevention (CDC), Antibiotic Prescribing and Use:
  https://www.cdc.gov/antibiotic-use/index.html
- Infectious Diseases Society of America (IDSA):
  http://www.idsociety.org/Index.aspx
- Society of Infectious Diseases Pharmacists (SIDP):
  http://sidp.org/
- The Joint Commission, Antimicrobial Stewardship:
  https://www.jointcommission.org/topics/hai_antimicrobial_stewardship.aspx
2. **ACUTE RHINOSINUSITIS**

**CONTENTS**

A. Key Points ................................................................................................................................................ 1
B. References ............................................................................................................................................... 2
C. About the Algorithm ................................................................................................................................ 2
D. Algorithm: Treatment of Rhinosinusitis.................................................................................................. 3

**A. Key Points**

- **DEFINITION:** Acute rhinosinusitis is defined as an inflammation of the mucosal lining of the nasal passage and paranasal sinuses, lasting up to four weeks.

- **CAUSES:** Causes of acute rhinosinusitis include allergens, environmental irritants, viruses, bacteria, and fungi.

- **DIAGNOSIS:** Most cases of diagnosed acute rhinosinusitis are due to uncomplicated viral upper respiratory tract infections. The prevalence of bacterial infection during acute rhinosinusitis is estimated to be 2–10%, whereas viral causes account for 90–98%.

  **However, any one of these three clinical presentations would indicate acute bacterial rhinosinusitis:**
  1. Onset with persistent symptoms lasting ≥ 10 days, without any evidence of clinical improvement.
  2. Onset with severe symptoms or signs of high fever (≥ 102°F), together with purulent nasal discharge or facial pain, lasting at least 3–4 consecutive days at the beginning of the illness.
  3. Onset with worsening symptoms or signs—characterized by a new onset of fever, headache, or increased nasal discharge—following a typical viral upper respiratory infection that lasted 5–6 days and was initially improving (“double sickening”).

- **ANTIMICROBIAL THERAPY** for acute bacterial rhinosinusitis (in adults) includes:
  1. **INITIAL EMPIRIC THERAPY:**
     - **First line:**
       - Amoxicillin-Clavulanate 500mg/125mg po tid **OR** 875mg/125 mg po bid
     - **Second line:**
       - Amoxicillin-Clavulanate ER 2000mg/125mg po bid
       - Doxycycline 100mg po bid **OR** 200mg po qd
  2. **BETA-LACTAM ALLERGY:**
     - Doxycycline 100mg po bid **OR** 200mg po qd
     - Levoﬂoxacin 500mg po qd
     - Moxifloxacin 400mg po qd
  3. **RISK FOR ANTIBIOTIC RESISTANCE OR FAILED INITIAL THERAPY:**
     - Amoxicillin-Clavulanate ER 2000mg/125mg po bid
     - Levoﬂoxacin 500mg po qd
     - Moxifloxacin 400mg po qd
B. References

- CDC. *Acute Bacterial Rhinosinusitis*. Available at: https://www.cdc.gov/getsmart/community/materials-references/print-materials/hcp/adult-acute-bact-rhino.pdf


C. About the Algorithm

- See algorithm on next page.
- Adapted from Chow AW, et al. (See above under *References*.)
D. Algorithm: Treatment of Acute Rhinosinusitis

Signs and symptoms are one of the following:
1. Persistent and not improving, lasting ≥10 days OR
2. Severe, lasting ≥3–4 days OR
3. Worsening or “double-sickening,” lasting ≥5–6 days

No

Symptomatic treatment only. Likely a viral infection and antibiotics are not indicated.

Yes

- Age <2 or >65, daycare?
- Prior antibiotics within the past month?
- Prior hospitalization in past 5 days?
- Comorbidities?
- Immunocompromised?

No

**FIRST LINE INITIAL THERAPY:** Amoxicillin-Clavulanate 500 mg/125 mg po tid OR 875 mg/125 mg po bid

Improvement in 3–5 days?

Yes

Complete 5–7 days of therapy.

No

Broaden coverage or switch to different antimicrobial class.

Improvement in 3–5 days?

Yes

Complete 5–7 days of therapy.

Second Line Initial Therapy:** Amoxicillin-Clavulanate ER 2000 mg/125 mg po bid OR Doxycycline 100 mg po bid OR Doxycycline 200 mg po qd

Improvement in 3–5 days?

Yes

Complete 7–10 days of therapy.

No

Broaden coverage or switch to different antimicrobial class.

Improvement in 3–5 days?

Yes

Complete 7–10 days of therapy.

No

Additional testing such as CT or MRI or sinus or meatal cultures may be indicated.

No

Complete 7–10 days of therapy.
3. PHARYNGITIS

CONTENTS

A. Key Points .................................................................................................................................................. 1
B. References: ................................................................................................................................................ 1
C. Algorithm: Treatment of Pharyngitis ........................................................................................................ 2

A. Key Points

- **TREATMENT:**
  - The large majority of adults with acute pharyngitis have a self-limiting illness that should be treated with supportive care only.
  - The benefits of antibiotic treatment of adult pharyngitis are limited to patients with group A streptococcal (GAS) infection. GAS is the etiologic agent in approximately 5–15% of adult cases of pharyngitis.

- **DIAGNOSIS:**
  - Clinical features alone are unreliable in differentiating between GAS and viral pharyngitis, except where overt viral features are present (e.g., rhinorrhea, cough, oral ulcers, and/or hoarseness).
  - Because the signs and symptoms of streptococcal and non-streptococcal (usually viral) pharyngitis overlap, diagnosis should be accomplished through laboratory testing with either a throat culture or a rapid antigen detection test (RADT).
  - Throat cultures are not recommended for confirming negative RADT results in adults. Throat cultures may be indicated when investigating outbreaks of GAS infection, as a means of monitoring the development and spread of antibiotic resistance, or when pathogens such as gonococcus are being considered.

B. References:


C. Algorithm: Treatment of Pharyngitis

### CLINICAL FEATURES
- Clinical features alone are unreliable in differentiating between viral pharyngitis and Group A streptococcal (GAS) infection. Up to 95% of pharyngitis cases are viral in nature; however, 5–15% of adult cases are the result of GAS infection.
- Clinically screen all patients suspected of pharyngitis for epidemiologic and clinical features suggestive of GAS and viral pharyngitis.

### BACTERIAL SYMPTOMS:
- Sudden onset of sore throat
- Age 5–15 years
- Fever
- Headache
- Nausea, vomiting, abdominal pain
- Tonsillopharyngeal inflammation
- Patchy tonsillopharyngeal exudates
- Palatal petechiae
- Anterior cervical adenitis (tender nodes)
- Winter and early spring presentation
- History of exposure to strep pharyngitis
- Scarlatiniform rash

### VIRAL SYMPTOMS:
- Conjunctivitis
- Coryza
- Cough
- Diarrhea
- Hoarseness
- Discrete ulcerative stomatitis
- Viral exanthema

#### RADT or throat culture should be completed in the absence of overt viral symptoms.

### POSITIVE RADT/CULTURE
- Treatment limited to patients with GAS
  - Penicillin V – 250 mg po qid or 500 mg po bid x 10 days
  - Amoxicillin ~1000 mg daily or 500 mg twice daily x 10 days

#### If Penicillin-Intolerant:
- Cephalexin – 500 mg po bid x 10 days

#### If Penicillin-Allergy (anaphylaxis):
- Azithromycin – 500mg po qd x 5 days
- Clarithromycin – 250mg po bid x 10 days
- Clindamycin – 300 mg po tid x10 days

### NEGATIVE RADT/CULTURE
- Antibiotics are not indicated.
  - Supportive care only.

### NOTES:
1. RADT tests should only be performed under structured waived testing programs, and each site must have their own CLIA waiver and ensure that the test being utilized is a CLIA-waived variety. Throat cultures are not recommended for confirming negative RADT results in adults. Throat cultures may be indicated when investigating outbreaks of GAS infection, as a means of monitoring the development and spread of antibiotic resistance, or when pathogens such as gonococcus are being considered.
2. Cephalexin or cefadroxil are preferred agents for penicillin-intolerant patients; however, they are to be avoided in individuals with immediate type hypersensitivity to penicillin.
   ➔ Consider pill line for patients with compliance concerns.
3. All patients with pharyngitis should be offered, or be referred to the commissary for, appropriate doses of analgesics, antipyretics, and other supportive care, in accordance with the BOP National Formulary Part I, Over the Counter Prescribing Criteria Matrix.

Adapted from: Shulman ST, et al. See References on previous page.
4. ACUTE BRONCHITIS

CONTENTS
A. Key Points ................................................................................................................................................ 1
B. Communicating with the Patient: Tips to Reduce Antibiotic Use ........................................................... 1
C. References ............................................................................................................................................... 1
D. Algorithm: Treatment of Acute Bronchitis ............................................................................................ 2

A. Key Points

• Acute bronchitis, also known as a “chest cold,” occurs when the airways in the lungs swell and produce mucus, causing a person to cough.

• Exposure to secondhand smoke, chemicals, dust, or air pollution can increase the risk for acute bronchitis. A weakened immune system or contact with another person with bronchitis can also increase the risk.

• Most causes (>90%) of acute bronchitis are viral in nature, and include respiratory syncytial virus, adenovirus, influenza, and parainfluenza.

• Signs and symptoms of acute bronchitis include coughing, fatigue, mild headache, mild body aches, fever, watery eyes, and sore throat. Most symptoms last for up to 2 weeks, but coughing can last up to 8 weeks.

  ★ The presence of purulent sputum is NOT predictive of bacterial infection.

• Diagnosis should include ruling out pneumonia. In healthy, non-elderly adult patients, pneumonia is uncommon in the absence of vital sign abnormalities or with findings of consolidation on lung auscultation.

B. Communicating with the Patient: Tips to Reduce Antibiotic Use

• Refer to acute cough illness as a “chest cold” to reduce the patient’s expectation for antibiotics.

• Tell patients that antibiotic use increases the risk of an antibiotic-resistant infection.

• Identify and validate the patient’s concerns and recommend specific therapy to address symptoms.

• Spend time answering questions and offer a contingency plan if symptoms worsen.

• REMEMBER: Effective communication is more important than an antibiotic for patient satisfaction.
C. References

- CDC. *Acute Cough Illness (Acute Bronchitis).* Available at: https://www.cdc.gov/getsmart/community/materials-references/print-materials/hcp/adult-acute-cough-illness.pdf
- CDC. *Bronchitis (Chest Cold).* Available at: https://www.cdc.gov/antibiotic-use/community/for-patients/common-illnesses/bronchitis.html

D. Algorithm: Treatment of Acute Bronchitis
5. PNEUMONIA

Contents

A. Key Points ................................................................................................................................................ 1
B. Etiologies of CAP ...................................................................................................................................... 2
C. Culture and Sensitivity (C&S) Notes ......................................................................................................... 2
D. Antibiotic Resistance ............................................................................................................................... 2
E. References................................................................................................................................................ 3
F. Algorithm: Treatment of CAP ................................................................................................................. 4

A. Key Points

• Pneumonia is divided into three types:
  > COMMUNITY-ACQUIRED PNEUMONIA (CAP) – An incidence of pneumonia demonstrated by select clinical signs and symptoms that occurs in the community or institutional setting.
  > HOSPITAL-ACQUIRED PNEUMONIA (HAP) – Refers to pneumonia that occurs at least 48 hours or more after admission, but was not incubating at the time of admission.
  > VENTILATOR-ASSOCIATED PNEUMONIA (VAP) – Refers to pneumonia that arises more than 48–72 hours after endotracheal intubation.

  ➔ This guidance focuses on the pathogens, diagnostic criteria, and treatment guidelines for CAP.

• DIAGNOSIS: Pneumonia is diagnosed according to suggestive clinical features (cough, fever, sputum production, pleuritic chest pain, leukocytosis), in addition to a demonstrable infiltrate by chest radiograph (or other imaging technique). Additional diagnostic tests may include the following, which are more routinely used in the presence of severe CAP, HAP, and VAP:
  > Pulse oximetry
  > Blood cultures
  > Sputum cultures/gram stain

  ➠ Prior to diagnosing pneumonia, providers should consider the possibility of tuberculosis and evaluate accordingly.

• SITE OF CARE RECOMMENDATION: The CURB-65 score is a severity-of-illness score that may be used to help determine whether a patient with CAP is a good candidate for outpatient treatment at the facility or whether the patient should be transferred to a higher level of care. Providers should always supplement this objective score with physical exam findings, any additional patient factors, and sound clinical judgment. A CURB-65 score ≥2 would suggest that the patient receive more intensive treatment (i.e., hospitalization).

CURB-65:
  Confusion (oriented x3)
  Uremia (BUN >20mg/dL)
  Respiratory Rate > 30
  Blood Pressure (SBP <90 or DBP <60)
  65 years or older
B. Most Common Etiologies of CAP

<table>
<thead>
<tr>
<th>Location of Care*</th>
<th>Etiology</th>
<th>Chlamydia pneumoniae</th>
<th>Mycoplasma pneumoniae</th>
<th>Respiratory viruses</th>
<th>Haemophilus influenzae</th>
<th>Streptococcus pneumoniae</th>
<th>Legionella species</th>
<th>Gram-negative bacilli</th>
<th>Staphylococcus aureus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inpatient (non-ICU)</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inpatient (ICU)</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

* LOCATION OF CARE is based on severity of disease.

C. Culture and Sensitivity (C&S) Notes

- Microbiological studies of blood and sputum cultures support the diagnosis of CAP, but are generally not required before initiating empiric treatment.
- At times, clinicians may suspect specific pathogens based on clinical and epidemiologic clues. If this is the case, providers are encouraged to further study these possibilities, as specific pathogens could significantly alter standard treatment decisions.
- Medical Centers are encouraged to create antibiograms to help guide prescribing.

D. Antibiotic Resistance

Resistance to commonly prescribed antibiotics for CAP is a major consideration in choosing empiric antibiotic treatment. Patient assessment for possible infection by multidrug resistant (MDR) pathogens is recommended to determine if alternate treatment should be considered.

Drug-resistant *Streptococcus pneumoniae* (DRSP) and community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) are two emerging pathogens that require special consideration.

- **Risk factors for DRSP include:**
  - Antibiotic use in the previous 3 months
  - Hospitalized in the past month
  - Immunosuppression (conditions or use of immunosuppressing drugs)
  - Presence of co-morbidities (e.g., chronic renal disease, liver disease, heart disease, lung disease, diabetes mellitus, alcoholism, malignancies, asplenia)

- **Risk factors for CA-MRSA include:**
  - End-stage renal disease
  - IV drug use
  - Prior influenza
  - Prior antibiotics
E. References


F. Algorithm: Treatment of CAP

- **DIAGNOSIS:** Clinical exam (cough, fever, sputum production, leukocytosis, pleuritic chest pain) and CXR; consider tuberculosis.
- **OTHER SUPPORTING DIAGNOSTIC CRITERIA (if indicated):** O2 sat, cultures (blood, sputum)

**EVALUATE SEVERITY (CURB-65):**
- Confusion (oriented x 3)
- Uremia (BUN >20 mg/dl)
- Respiratory Rate > 30
- BP (SBP <90 or DBP <60)
- 65 y/o or greater

**CURB-65 score: 0-1 (mild)**
- Consider outpatient care.

**CURB-65 score: 2 (moderate)**
- Consider inpatient management (non-ICU).

**CURB-65 score: ≥ 3**
- Refer to IDSA CAP guidelines.

**ASSESS FOR DRSP:**
- Antibiotic use in previous 3 months?
- Hospitalized in past month?
- Immunosuppression?
- Multiple co-morbidities? (renal, heart, lung disease, DM, alcoholism, etc.)

**NO DRSP RISK**

**PREFERRED:**
- Azithromycin or
- Erythromycin or
- Clarithromycin

**ALTERNATIVE:**
- Doxycycline

**DRSP RISK (≥1 risk factor)**

**PREFERRED:**
- Levofloxacin or
- Moxifloxacin

**ALTERNATIVES:**
- Beta-lactam
  - Ampicillin/ceftriaxone/cefotaxime
  - AND -
- Azithromycin or
- Erythromycin or
- Clarithromycin

**If hospitalized & initial therapy is not successful, treat as severely ill (HAP).**

**NOTE:** Dose and duration are not included here due to the large number of variables that may be present. Questions regarding dose and duration should be directed to the IDSA guidelines, an antimicrobial stewardship team member, or a pharmacist.

Adapted from: Mandell LA, et al. See References on previous page.
6. OTITIS MEDIA

CONTENTS
A. Bacterial Etiologies ................................................................................................................................... 1
B. Key Points ................................................................................................................................................. 1
C. Diagnosis .................................................................................................................................................. 1
D. Empiric Antibiotic Therapy ...................................................................................................................... 2
E. Antibiotic Therapy for Treatment Failure ................................................................................................ 2
F. References ................................................................................................................................................ 2

A. Bacterial Etiologies

- Streptococcus pneumoniae (49%)
- Haemophilus influenzae (29%)
- Moraxella catarrhalis (28%)

B. Key Points

- **ACUTE OTITIS MEDIA (AOM)** occurs primarily in childhood. Diagnosis and treatment is therefore largely extrapolated from studies in children,
- Seasonal allergic rhinitis and/or upper respiratory infections are the most important pathological factors in the development of AOM
- Clindamycin is not active against *H. influenzae* or *M. catarrhalis*, two common bacterial contributors of otitis media.
- Due to the prevalence of drug-resistant *Strep. pneumoniae*, trimethoprim/sulfamethoxazole and macrolides are no longer recommended.
  - Up to 50% of *Strep. Pneumoniae* is resistant to macrolides.
  - *Strep. Pneumoniae* that is resistant to macrolides is also typically resistant to clindamycin.

C. Diagnosis

- AOM is usually marked by the presence of middle ear fluid and inflammation of the mucosa that lines the middle ear space.
- AOM is often caused by obstruction of the eustachian tube, resulting in fluid retention and suppuration of retained secretions.
- A triad of bulging tympanic membrane, impaired tympanic membrane mobility, and redness and/or opacification of tympanic membrane predicted the diagnosis of AOM in 83–99% of cases. If these three are not present, the provider should consider other possible diagnoses.
- Purulent otorrhea may be present with tympanic membrane rupture.
- AOM is usually unilateral, and hallmark symptoms include otalgia and decreased hearing.

(list continues on next page)
• Other clinical manifestations include conductive hearing loss, fever, pain behind the ear, and facial paralysis.

• Otitis media with effusion (OEM), also known as serous otitis media, usually follows AOM. It is defined by the presence of middle ear fluid without signs of illness or inflammation of the middle ear mucosa.
  * OEM usually resolves spontaneously and does not require antibiotic treatment.

D. Empiric Antibiotic Therapy

• **Amoxicillin remains the drug of choice:**
  - Mild to moderate disease: 500 mg every 12 hours.
  - Severe disease: 500 mg every 8 hours.
  - Doses up to 2 grams every 8 hours have been used and are indicated in areas where the local antibiogram indicates strains of *S. pneumoniae* that are not fully susceptible to penicillin.
  - If severe penicillin allergy (i.e., anaphylaxis), a macrolide (azithromycin or clarithromycin) is preferred.

• **Duration of treatment:**
  - Mild to moderate disease: 5–7 days.
  - Severe disease: 10 days.
  - Improvement should be seen within 48 to 72 hours. If there is no improvement, the patient should be reexamined and treated as below.

E. Antibiotic Therapy for Treatment Failure

• Treatment failure after 3 days of therapy indicates concern for drug-resistant *S. pneumoniae*.

• An agent with broader coverage than the initial therapy is recommended:
  - Amoxicillin-clavulanate 2000 mg/125 mg bid.
  - For patients with severe penicillin allergies, please contact a member of the Antimicrobial Stewardship Workgroup for alternative antibiotic recommendations.

• Duration of treatment after treatment failure is 10 days.

• Although levofloxacin and ceftriaxone may be viable therapy options, they should be reserved for only those patients with absolute contraindications to amoxicillin-clavulanate.

F. References


7. **PURULENT SKIN AND SOFT TISSUE INFECTIONS (SSTIs), INCLUDING MRSA**

**A. Key Points**

**Purulent SSTIs** include cutaneous abscesses, furuncles, carbuncles, folliculitis, and *methicillin-resistant Staphylococcus aureus (MRSA)*.

- **CUTANEOUS ABSCESS**es are collections of pus within the dermis and deeper skin tissues that are typically painful, tender, and fluctuant red nodules surrounded by inflamed tissue.
  - **FURUNCLES** (also known as **BOILS**) are infections of the hair follicle and adjacent tissue, forming a hard central core and pus that extends through the dermis into the subcutaneous tissue.
  - **CARBUNCLES** are similar to furuncles, but involve several adjacent follicles that drain pus.
  - **FOLLICULITIS** is inflammation of the hair follicle that appears clinically as an eruption of **pustules** and/or **papules** centered upon hair follicles.

**NOTE:** The term “cellulitis” is **NOT** appropriate for cutaneous inflammation associated with collections of pus such as in septic bursitis, furuncles, or skin abscesses. In **such cases of purulent infection, the appropriate terminology is “with surrounding inflammation,” and NOT “with surrounding cellulitis.” This distinction is critical.** The treatment of purulent infections is with incision and drainage (I&D), whereas the treatment of cellulitis is with antibiotics. (See Chapter 8 for more about cellulitis and other non-purulent SSTIs.)

- **COLONIZATION** is the presence of bacteria on or in the body without causing infection.
- **INCISION AND DRAINAGE (I&D)** is the recommended treatment for both non-MRSA and MRSA-suspected abscesses, carbuncles, and large furuncles that are not accompanied by systemic signs of infection.
  - The addition of systemic antibiotics to I&D does **NOT** improve cure rates in these cases.
  - Smaller furuncles often rupture and drain spontaneously or after treatment with moist heat (**WARM SOAKS AND COMPRESSIONS**).
• Systemic antibiotics are warranted in the presence of **SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS)**, indicated by temperature >38°C or <36°C, tachypnea >24 breaths per minute, tachycardia >90 beats per minute, or white blood cell count >12,000 or <400 cells/μL.

• **ORAL ANTIBIOTIC THERAPY** can be provided to patients with SSTIs that do not involve either significant cellulitic changes or signs/symptoms of systemic infection.

• **IV ANTIBIOTIC THERAPY** is needed for systemic infections, significant cellulitis, endocarditis and other endovascular infections, osteomyelitis, necrotizing fasciitis, pneumonia.

• **THE CAUSE FOR RECURRENT ABSCESSES** at a particular site should be determined, including the possibility of a pilonidal cyst, hidradenitis suppurativa, or foreign material.

• **PATIENT EDUCATION** is crucial for effective treatment and the prevention of transmission of SSTIs. Inmate factsheets, *General Instructions for Skin Infections* and *Information on MRSA*, are available in Sections G and H of this chapter.

**B. Culture and Sensitivity (C&S)**

• C&S results are used to direct and streamline therapy.

• Consider for moderate to severe infections, and those requiring IV therapy.

• Culturing of areas that are normally colonized is of little value. Culturing of wounds can often include normal skin flora. Samples should be taken from areas that are not normally colonized (e.g., wounds) by a clinician experienced in obtaining sterile cultures.

• Culture diagnosis should be obtained whenever clinically warranted, including:
  > For patients with recurrent SSTIs.
  > For an SSTI that is not resolving with current treatment.
  > As part of periodic surveillance to determine the predominant circulating pathogens in a given facility.

• Cultures from abscesses and other purulent SSTIs are recommended in the following cases:
  > If the provider believes antibiotic therapy is indicated for the patient.
  > For patients with severe local infection or signs of systemic illness.
  > For patients who have not responded adequately to initial treatment.
  > If there is concern for a cluster or outbreak.

• Positive diagnostic cultures include cultures from blood, sterile body fluids (e.g., joint fluid, pleural fluid, cerebrospinal fluid), expressed pus that avoids skin contamination, and aspirated abscess fluid.
C. Empiric Treatment

> See Treatment Algorithm in Section E.

**CONSERVATIVE AND MECHANICAL TREATMENT MEASURES**

- The primary treatment of choice for cutaneous abscesses is I&D and/or warm compresses.
  > See Section F for I&D Procedure and see the Treatment Algorithm for information on using warm soaks and compresses.
- While smaller furuncles often rupture and drain spontaneously—or after treatment with moist heat—I&D is the recommended treatment for both non-MRSA and MRSA-suspected abscesses, carbuncles, and large furuncles that are not accompanied by systemic signs of infection.
  > An indication of the presence of pus in a bacterial skin infection is fluctuance: As the skin becomes infected, redness and induration (hardness) develop. If the pus does not drain, touching this area produces a soft, boggy feel known as fluctuance. In general, fluctuant lesions need to be incised and drained.
  > The addition of systemic antibiotics to I&D does not improve cure rates in these cases.
  > Once the abscess is drained, frequently reassess to determine whether repeated I&D is warranted.

**ANTIBIOTIC THERAPY**

★ The decision to initiate antibiotic treatment should be based on culture and sensitivity results when possible. The use of antibiotics for the suspected presence of MRSA should be reserved for the following:

- Severe or extensive disease (e.g., involving multiple sites of infection) or rapid progression in the presence of associated cellulitis.
- Signs and symptoms of systemic illness.
- Associated comorbidities or immunosuppression (diabetes mellitus, HIV/AIDS, neoplasm).
- Extremes of age.
- Abscess in an area difficult to drain completely (e.g., face, hand, genitalia).
- Associated septic phlebitis.
- Lack of response to I&D alone.

**DECOLONIZATION OF MRSA INFECTIONS**

Decolonization is the use of antimicrobial or antiseptic agents to suppress or eliminate *S. aureus* to aid in preventing recurrent auto-infection or transmission to others.

- Decolonization is NOT routinely recommended.
- The efficacy of decolonization has NOT been well-established.

(continues on next page)
Two circumstances in which decolonization can be considered are described in the table below:

<table>
<thead>
<tr>
<th>Circumstances of MRSA Infection</th>
<th>Decolonization Procedure*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INMATES WITH RECURRENT MRSA INFECTIONS</strong> (e.g., three or more infections in less than six months)</td>
<td><strong>FOR 5–10 DAYS:</strong></td>
</tr>
<tr>
<td><strong>OUTBREAK SITUATIONS</strong> in which ongoing MRSA transmission is occurring among a well-defined cohort with close contact.</td>
<td></td>
</tr>
<tr>
<td>➔ Requires consultation with Central Office infection control.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>➔ Due to security concerns related to chlorhexidine formulations, the judicious use of chlorhexidine for decolonization is recommended on a case-by-case basis. Chlorhexidine formulations should NOT be dispensed directly to the inmate as a self-carry.</td>
</tr>
</tbody>
</table>

* Surveillance cultures following decolonization are NOT recommended in the absence of active infection.

D. References

E. Algorithm: Treatment of Purulent SSTIs

**PURULENT INFECTION**
Abscess /Furuncle/Carbuncle

- **MILD**
  - I&D/Warm Soaks & Compresses

- **MODERATE**
  - I&D/Warm Soaks & Compresses (consider C&S)
    - **EMPIRIC RX:**
      - TMP/SMX
      - Doxycycline
    - **C&S-DEFINED RX:**
      - **MRSA**
        - TMP/SMX
      - **MSSA**
        - Dicloxacillin
        - Cephalexin

- **SEVERE**
  - I&D/C&S/Warm Soaks & Compresses
    - **EMPIRIC RX:**
      - Vancomycin or
      - Daptomycin or
      - Linezolid or
      - Televancin or
      - Ceftaroline
    - **C&S-DEFINED RX:**
      - **MRSA**
        - See EMPIRIC RX.
      - **MSSA**
        - Nafcillin or
        - Cefazolin or
        - Clindamycin

**DEFINITIONS:**
- **MILD:** No signs of systemic infection.
- **MODERATE:** Systemic signs of infection.
- **SEVERE:** Patients who have failed I&D plus oral antibiotics OR patients with systemic signs of infection plus hypotension (see SIRS in Section A).
- **I&I:** Incision and drainage (see Section F for I&D Procedure).
- **C&S:** Culture and sensitivity (see Section B for information on C&S).
- **MRSA:** Methicillin-resistant *Staphylococcus aureus*
- **MSSA:** Methicillin-sensitive *Staphylococcus aureus*
- **TMP/SMX:** Trimethoprim/sulfamethoxazole

**WARM SOAKS AND COMPRESSIONS:**
- Soak the infected area in warm water for 20 minutes, 2–3 times a day or apply a heating pad or a warm, moist clean washcloth to the area for 20 minutes, 2–3 times a day.
- Decisions about how to safely implement warm soaks and/or compresses in the correctional setting must be made on a case-by-case basis, in consultation with the infection control officer.

**ADAPTED FROM:** Figure 1 in [http://cid.oxfordjournals.org/content/early/2014/06/14/cid.ciu296.full.pdf+html](http://cid.oxfordjournals.org/content/early/2014/06/14/cid.ciu296.full.pdf+html)

**NOTE:** Providers should consult with a pharmacist for assistance with medication selection, specific dosing recommendations, and medication monitoring.
F. Incision and Drainage (I&D) Procedure

Abscesses are localized infections of tissue marked by a collection of pus surrounded by inflamed tissue. Abscesses may be found in any area of the body, but most abscesses presenting for urgent attention are found on the extremities, buttocks, breast, perianal area, axilla, groin, or hair follicles (furuncles and carbuncles). Abscesses begin when the normal skin barrier is breached, and microorganisms colonize the underlying tissues. Causative organisms commonly include Streptococcus sp., Staphylococcus sp., enteric bacteria (perianal abscesses), or a combination of anaerobic and gram-negative organisms.

Abscesses resolve by drainage:
- Smaller abscesses may resolve with conservative measures (see description of warm soaks above in the Algorithm) to promote spontaneous drainage.
- Larger abscesses will require incision to drain them (I&D), since the increased inflammation, pus collection, and walling-off of the abscess cavity diminish the effectiveness of antibiotic treatment. Healing following an I&D should progress from the inside of the abscess outward to the incision site. This will require a gauze packing to promote healing from the inside outward.

Indication for I&D
Abscess within the skin that is palpable.

Contraindications for I&D
- Extremely large abscesses that require extensive incision, debridement, or irrigation—best done in operating room.
- Deep abscesses in very sensitive areas (labial, supraventricular, ischiorectal, perirectal)—require a general anesthetic to obtain proper exposure.
- Abscess in the hands or feet.
- Abscesses in the triangle formed by the bridge of the nose and the corners of the mouth—should generally be treated with warm compresses and aggressive antibiotic therapy.
- Abscesses located near major vessels—must be differentiated from aneurysms before I&D is performed, to avoid fatal hemorrhage. The distinction is made through aspiration with a large bore needle.

Materials
- Sterile gloves
- Mask/eye protection, if abscess appears to be under pressure enough to cause expulsion of contents with the incision
- Local anesthesia: 1% or 2% lidocaine with epinephrine; 10 cc syringe and 23-gauge needle for infiltration. (Note: Epinephrine is contraindicated in areas such as the fingers, nose, toes, and penis). Alternatively, diphenhydramine (Benadryl) 10 to 25 mg can be used for anesthesia. Dilute a 50 mg (1 cc) vial in a syringe with 4 cc of normal saline.
- Alcohol or povidone-iodine wipes

(list of I&D materials continued on next page)
Pre-procedure education

- Obtain informed consent. Inform the patient of potential severe complications and their treatment.
- Explain the steps of the procedure, including the pain associated with anesthetic infiltration.

I&D procedure

1. Use Standard Precautions.
2. Cleanse site over abscess with skin preparation of choice.
3. Drape to create a sterile field.
4. Infiltrate local anesthetic, allowing 2–3 minutes for anesthetic to take effect.
5. Incise over abscess with the #11 blade, cutting through the skin into the abscess cavity. Follow skin fold lines whenever possible while making the incision. The incision should be sufficiently wide to allow the abscess to drain and to prevent premature closure of the incision. For smaller abscesses requiring incisions, a “stab” or “cruciate” incision should be adequate. Some refer to this as a puncture or stab technique since the operator inserts the tip of the scalpel directly into the center of the abscessed tissue without making a linear incision.
6. Allow the pus to drain, using the gauzes to soak up drainage and blood. If a culture is being obtained, use the culture swab to take culture of abscess contents, swabbing inside the abscess cavity—not from the superficial skin over the abscess.
7. Use the hemostat or sterile cotton-tipped applicator to gently explore the abscess cavity to break up any locations within the abscess.
8. Loosely pack the abscess cavity with the packing.
9. Place gauze dressing over the wound, and tape in place (without placing tape over the incision site).
10. Remove gloves and wash hands. Properly dispose of contaminated articles and assure appropriate cleaning of the area.
11. Schedule a call-out within 24–48 hours post-op. Depending upon the location and size of the abscess, arrange for the packing material to be changed daily or several times per day.
12. Pain from the site may require acetaminophen or nonsteroidal anti-inflammatory drugs; narcotics are rarely needed. With a tense abscess, the pain relief associated with the I&D itself may be sufficient so that no pain medication is required.
POST-PROCEDURE PATIENT EDUCATION

An Inmate Fact Sheet—General Instructions for Skin Infections is available in Section G.

Symptoms: Patients should be instructed to watch for the following, and be advised to seek medical attention if they experience such symptoms:
- Re-collection of pus in the abscess.
- Fever and chills.
- Increased pain and redness.
- Red streaks near the abscess.
- Increased swelling.

Self-care: While some inmates will need to return to the clinic to have their dressings changed, others can be taught to do this for themselves. In addition to showing these patients how to change the packing and replace the dressings, they should be educated on:
- Disposal of dressing material.
- Hand-washing technique.
- Cleansing the area after the dressing is complete.

I&D COMPLICATIONS

Prevention and management of complications associated with I&D are outlined below.

<table>
<thead>
<tr>
<th>Complication</th>
<th>Prevention/Cause</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insufficient anesthesia</td>
<td>Keep in mind that the tissue around an abscess is acidotic, and that local anesthetic loses effectiveness in acidotic tissues.</td>
<td>Do a field block. Use sufficient quantity of anesthetic. Allow time for anesthetic effect.</td>
</tr>
<tr>
<td>No drainage</td>
<td>Localize site of incision by palpation.</td>
<td>Extend incision deeper or wider as needed.</td>
</tr>
<tr>
<td>Drainage is sebaceous material</td>
<td>Abscess was an inflamed sebaceous cyst.</td>
<td>Express all material. Break up sac with hemostat. Pack open, as with an abscess.</td>
</tr>
</tbody>
</table>

- Following I&D of any abscess, the site should be observed for signs of re-collection of pus or cellulitis.
- Complications of an inadequately treated abscess include bacteremia and septicemia.
- In persons who are immunocompromised, particularly diabetics, an abscess on an extremity can be complicated by severe cellulitis or gangrene, with potential loss of the affected extremity.
- An I&D of a perianal abscess frequently results in a chronic anal fistula that requires fistulectomy by a surgeon.
- Deep palmar abscesses are a surgical emergency.

DOCUMENTATION OF I&D ON THE MEDICAL RECORD

- Informed consent (signed).
- Procedure used, prep, anesthetic (type and quantity), success of drainage, culture if collected.
- Any complications (or “none”).
- Who was notified of any complication (APP, attending MD).
- Follow-up arrangements for scheduled call-out and dressing changes.
### G. Inmate Fact Sheet—General Instructions for Skin Infections

<table>
<thead>
<tr>
<th>Handwashing and General Hygiene</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Regularly wash your hands with soap and water for at least 15 seconds, especially:</td>
</tr>
<tr>
<td>&gt; Before and after using the toilet.</td>
</tr>
<tr>
<td>&gt; Before and after touching your wound.</td>
</tr>
<tr>
<td>&gt; Before eating.</td>
</tr>
<tr>
<td>• Shower frequently and put on clean clothes. Change your clothing whenever they become soiled with wound drainage.</td>
</tr>
<tr>
<td>• Change bed linens and towels regularly and whenever they become soiled with wound drainage.</td>
</tr>
<tr>
<td>• Do not share personal items such as razors, towels, wash cloths, bars of soap, etc.</td>
</tr>
<tr>
<td>• If you have an open wound, it should be covered at all times with a bandage.</td>
</tr>
<tr>
<td>• Do not allow other inmates to touch your wound.</td>
</tr>
<tr>
<td>• If your bandage comes off, dispose of it carefully in a leak-proof container as instructed by health services staff. Then, wash your hands. Inform a correctional worker that you need a new bandage.</td>
</tr>
<tr>
<td>• You cannot work in Food Service if you have a draining wound on your hands, or if you have wounds located elsewhere and wound drainage is not contained by a bandage.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Warm Soaks and Compresses</th>
</tr>
</thead>
<tbody>
<tr>
<td>You may be instructed to soak your skin infection regularly in warm salt water, or apply moist compresses for 20 minutes at a time. Carefully follow the instructions you receive. If your wound begins to drain, report it to the health center.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Take all medications prescribed by your doctor—exactly as you are told.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Report any of the following to the health center:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Fever</td>
</tr>
<tr>
<td>• Red streaks up from the wound</td>
</tr>
<tr>
<td>• Increased foul smell from wound drainage</td>
</tr>
<tr>
<td>• Increased wound drainage</td>
</tr>
</tbody>
</table>
## What is MRSA?

- *Staphylococcus aureus*, often referred to as “staph,” is a common type of bacteria that is found on the skin and in the nose of healthy persons. Staph bacteria may cause minor skin infections such as boils, or more serious infections such as pneumonia and blood poisoning.
- Certain “staph” bacteria that have become resistant to the usual “first-line” antibiotics are called **MRSA**—which is short for “methicillin-resistant *Staphylococcus aureus*.” MRSA infections are more difficult to treat, but they usually respond to “incision and drainage” and/or stronger antibiotics.

## How is MRSA spread from person to person?

- MRSA is usually spread through direct physical contact with an infected person, but may also be transmitted through contact with contaminated objects or surfaces.
- MRSA is **NOT** spread by coughing unless the infected person has pneumonia.

## How can you prevent becoming infected with MRSA?

- Wash your hands thoroughly with soap and water throughout the day, particularly every time you use the toilet and before every meal.
- Never touch another person’s wounds, infected skin, or dirty bandages.
- Don’t scratch skin rashes.
- Maintain personal hygiene through regular showers and by keeping your living space clean, including regularly laundering your bed linens.
- Do not hand-wash and air dry your laundry. Use the institutional laundry.
- Never share personal hygiene items with others, including toiletries or towels.
- Clean off any surfaces shared with others, such as weight benches.
- Use a towel or shirt as a barrier between your bare skin and exercise equipment.
- Shower after participating in close-contact recreational activities whenever possible.
- Don’t get a tattoo in prison.
- Don’t use injection drugs.
- Don’t have sexual contact with other inmates.
- Shower before participating in sweat lodges and wear clean clothes. Then, shower after the sweat lodge.

## How do you know if you have a MRSA infection?

- Always seek medical attention if you develop a boil, red or inflamed skin, an infected insect or spider bite, or a sore that does not go away.
- The most common way for health care providers to detect MRSA is by doing a culture of the pus from the skin infection.

## How is MRSA treated?

- MRSA skin infections are often treated first with frequent warm soaks and draining of the wound.
- Strong antibiotics can be effective in treating MRSA.
- Serious or highly resistant MRSA infections may require intravenous (IV) antibiotics in the hospital.
A. Key Points

Non-purulent SSTIs include CELLULITIS, Erysipelas, and NECROTIZING INFECTION.

- **CELLULITIS** and **ERYSIPELAS** refer to diffuse, superficial, spreading skin infections. These infections cause rapidly spreading areas of erythema, swelling, tenderness, and warmth, and are caused by a bacterial breach in the skin.
  - **ERYTHEMA** is blanchable redness of the skin, which can be localized or generalized, and is caused by dilation of superficial blood vessels and capillaries near the skin’s surface.
  - The term **CELLULITIS** is NOT appropriate for cutaneous inflammation associated with collections of pus such as in septic bursitis, furuncles, or skin abscesses.
    - In such cases of purulent infection, the appropriate terminology is “with surrounding inflammation” and NOT “with surrounding cellulitis.”
    - ★ This distinction is critical. The treatment of purulent infections is with incision and drainage (I&D), whereas the treatment of cellulitis is with antibiotics. (See Chapter 7 for information on the treatment on purulent SSTIs.)
  - Typical cases of cellulitis should include an antibiotic active against streptococci.
  - In cases of uncomplicated cellulitis, a 5-day course of antimicrobial therapy is adequate.
  - Methicillin-resistant *Staphylococcus aureus* (MRSA) is an unusual cause of typical cellulitis, but coverage may be prudent in cellulitis associated with penetrating trauma (especially from illicit drug use), purulent drainage, or with concurrent evidence of MRSA infection elsewhere. (See more information on the treatment of MRSA in Chapter 7.)

- **NECROTIZING INFECTIONS** are deep infections involving fascial and/or muscle compartments and causing major tissue destruction. The initial presentation is that of cellulitis, which can advance rapidly or slowly. As it progresses, there is systemic toxicity including high temperatures, disorientation, and lethargy.
  - ★ A distinguishing feature is the wooden-hard induration of the subcutaneous tissues.
B. References

- Baddour LM. Cellulitis and erysipelas. In: Up to Date, Sexton DJ, Kaplan SL, eds. Up to Date, Waltham, Massachusetts. Available at: http://www.uptodate.com/contents/cellulitis-and-erysipelas?source=see_link


C. Algorithm: Treatment of Non-Purulent SSTIs

NON-PURULENT INFECTION
Necrotizing Infection/Cellulitis/Erysipelas

MILD

ORAL RX:
Penicillin VK or
Cefalosporin or
Dicloxacillin or
Clindamycin

MODERATE

INTRAVENTOUS RX:
• Penicillin or
• Ceftriaxone or
• Cefazolin or
• Clindamycin

SEVERE

EMERGENT SURGICAL INSPECTION/DEBRIDEMENT:
Rule out necrotizing infection

EMPIRIC RX:
• Vancomycin PLUS Piperacillin/Tazobactam

C&S

DEFINED RX (NECROTIZING INFECTIONS):

MONOMICROBIAL
Streptococcus pyogenes:
• Penicillin PLUS Clindamycin
Clostridial sp.:
• Penicillin PLUS Clindamycin
Vibrio vulnificus:
• Doxycycline PLUS Ceftazidime
Aeromonas hydrophila:
• Doxycycline PLUS Ciprofloxacin

POLYMICROBIAL
• Vancomycin PLUS Piperacillin/Tazobactam

DEFINITIONS:
MILD: Typical cellulitis/erysipelas without systemic signs of infection
MODERATE: Typical cellulitis/erysipelas with systemic signs of infection.
SEVERE: Patients who have failed oral antibiotic treatment; or who have systemic signs of infection; or who are immunocompromised; or who have clinical signs of deeper infection such as bullae, skin sloughing, hypotension, or evidence or organ dysfunction.
C&S: Culture and sensitivity.
Adapted from: Figure 1 in http://cid.oxfordjournals.org/content/early/2014/06/14/cid.ciu296.full.pdf+html
9. **Clostridium difficile Infection**

**Contents**
- A. Key Points ................................................................................................................................................ 1
- B. Diagnosis and Classification ..................................................................................................................... 2
- C. Treatment ................................................................................................................................................ 3
- D. Infection Control and Prevention ............................................................................................................ 3
- E. References ................................................................................................................................................ 4

**A. Key Points**

- *Clostridium difficile* (*C. difficile*) is a non-invasive, Gram-positive, spore-forming bacterium that causes disease through production of toxins A and B. Disease severity ranges from asymptomatic carriage to pseudomembranous colitis.

- *C. difficile Infection* (CDI) is manifested as acute onset diarrhea resulting from toxigenic *C. difficile*.

- **Primary risk factors** for CDI include the following:
  - **Antibiotic exposure**: Especially to clindamycin, fluoroquinolones, and second- or higher-generation cephalosporins; to a lesser extent, penicillins, macrolides (i.e., azithromycin, clarithromycin), medications with beta lactamase inhibitors (i.e., amoxicillin/clavulanic acid, piperacillin/tazobactam), and carbapenems.
    - *If CDI is suspected or diagnosed, any antibiotics potentially contributing to the development of CDI should be discontinued unless they are absolutely indicated.*
  - **Exposure to the organism itself**
  - **Other notable risk factors**: Use of acid-lowering medications (e.g., omeprazole, ranitidine, etc.), gastrointestinal tract manipulation, comorbid conditions (e.g., inflammatory bowel disease, immunosuppression, pregnancy), age, hospital admission, and duration of stay in hospital or long-term care facility.

- **Empiric CDI treatment may be considered**, regardless of laboratory test result, in the context of high clinical suspicion—due to risk of a false negative.

- **Symptomatic treatment with anti-peristaltic medications (e.g., loperamide) should be avoided**, as they can precipitate severe disease and potentially mask symptoms, thereby interfering with the monitoring of CDI resolution.

- **Laboratory confirmation of cure should not be performed**. False positives are common, complicating care and contributing to inappropriate antibiotic use.

- **Recurrent *C. difficile infection* (RCDI)** is thought to be largely linked to altered colonic microbiota. 10–20% of patients with CDI will suffer RCDI within 8 weeks of completing the initial CDI treatment regimen. Of these patients, the rates of further recurrence range from 40–65%. Identification of RCDI is necessary to select appropriate treatment, particularly beyond the first recurrence. (See more information in the table under Treatment below.)

- Use of probiotics is discussed in *Chapter 10* of the Antimicrobial Stewardship Clinical Guidance.
B. Diagnosis and Classification

**DIAGNOSIS** is made after pre-screening for symptoms (e.g., active diarrhea) and risk factors. Testing of stools from patients with diarrhea should be done by utilizing one of the following methods:

- **NUCLEIC ACID AMPLIFICATION TEST (NAAT)** for toxigenic *C. difficile* (e.g., PCR assay)
  - Use only in the context of documented diarrhea, due to risk of false positive.

- **GLUTAMATE DEHYDROGENASE SCREENING TEST**, followed by confirmation with either NAAT or toxin A + B enzyme immunoassay (EIA)
  - NAAT may be preferred for confirmation due to higher sensitivity than EIA.

**CLASSIFICATION OF SEVERITY** is necessary in order to select the appropriate treatment:

- **Mild**: Diarrhea is the only symptom.
- **Moderate**: Diarrhea and other symptoms are present, but do not meet criteria for either **Severe** or **Severe and Complicated** (see below).
- **Severe**: Presence or development of hypoalbuminemia (albumin <3g/dl), **plus either**:
  - WBC ≥15,000/ml, or
  - Abdominal tenderness NOT meeting criteria for **Complicated** (see below)
- **Severe and Complicated**: Meeting criteria for **Severe** (see above) **plus** presence or development of at least one of the following complications:
  - Admission to intensive care unit (ICU)
  - Hypotension (with or without vasopressors)
  - Fever ≥ 38.5°C
  - Ileus
  - Significant abdominal distension
  - Mental status changes
  - WBC ≥ 35,000/ml or <2,000/ml
  - Serum lactate > 2.2mmol/ml
  - Evidence of end organ failure
C. Treatment

<table>
<thead>
<tr>
<th>Severity</th>
<th>Treatment</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild–Moderate</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; line: Metronidazole 500mg PO three times a day for 10 days.*</td>
<td>If no improvement within 5–7 days with 1&lt;sup&gt;st&lt;/sup&gt; line regimen, consider change to 2&lt;sup&gt;nd&lt;/sup&gt; line regimen.</td>
</tr>
<tr>
<td></td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; line (e.g., pregnancy): Vancomycin 125mg PO four times a day for 10 days.</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>Vancomycin 125mg PO four times a day for 10 days.**</td>
<td></td>
</tr>
<tr>
<td>Severe and Complicated</td>
<td>Vancomycin 500mg PO four times a day and metronidazole 500mg IV every 8 hours.*</td>
<td>Surgical consult is recommended.</td>
</tr>
<tr>
<td></td>
<td>Add vancomycin 500mg in 500ml saline as rectal enema four times a day, if ileus is present.</td>
<td></td>
</tr>
<tr>
<td>Initial RCDI *** (within 8 weeks of completing prior treatment)</td>
<td>Confirm level of severity and treat as described above.</td>
<td></td>
</tr>
</tbody>
</table>

* Metronidazole should NOT be used beyond the first RCDI.

** A 10-day course of fidaxomicin 200mg PO twice a day may be considered INSTEAD of vancomycin regimen in patients with severe, uncomplicated infection who are at particularly high risk of recurrence (e.g., when causative antibiotic cannot be discontinued).

*** Discussion of patients with RCDIs beyond the initial RCDI is outside the scope of this guidance. Such cases should be managed on a case-by-case basis, and consultation with a specialist should be considered. Possible treatment may include pulsed and/or tapered regimens, with or without rifaximin or fidaxomicin “chasers,” or fecal microbiota transplant.

*Note:* Oral vancomycin doses may be compounded from the intravenous formulations at capable institutions at significant cost savings.

D. Infection Control and Prevention

- Contact precautions should be maintained for all CDI patients, at least until diarrhea resolves.
- Gloves and gowns should be worn by all individuals entering the room of any CDI patient.
- Hand hygiene should be performed using soap and water; alcohol-based and chlorhexidine-based sanitizers are NOT as effective against *C. difficile* spores.
- Disinfection of environmental surfaces should be performed with a *C. difficile*-sporicidal disinfectant.
- There is not enough evidence to show that probiotics prevent CDI. See Chapter 10 of the *Antimicrobial Stewardship Clinical Guidance* for more information on probiotics.
E. References


10. PROBIOTICS

CONTENTS
A. Key Points ................................................................................................................................................ 1
B. References ............................................................................................................................................... 2

A. Key Points

- Microbiological studies and current literature suggest an alteration or imbalance in gastrointestinal (GI) bacteria may be causative in *Clostridium difficile* (*C. difficile*) infections and may cause symptoms in individuals with inflammatory bowel disease (IBD).

- The Food and Drug Administration (FDA) classifies probiotics as supplements. As such, their content and dose vary from brand to brand. According to the FDA, “supplements are not intended to treat, diagnose, prevent, or cure diseases.”

*C. difficile*

- No current GI or infectious disease guidelines recommend routine probiotic use for prevention or treatment of *C. difficile*.

- Several studies have investigated the use of probiotics for treatment and prevention. However, current literature is inconsistent, and no strong evidence supports routine probiotic use for prevention or treatment.

**INFLAMMATORY BOWEL DISEASE**

- Available literature does not support probiotic supplementation for treatment of Crohn’s disease at this time.

- While there are small studies that reflect that there may be a benefit with certain strains of probiotics in ulcerative colitis, the data is weak and further studies are needed prior to recommending their use.

---

4 [http://www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm109760.htm](http://www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm109760.htm)
B. References


- Evans CT, Johnson S. Prevention of *Clostridium difficile* infection with probiotics. *Clin Infect Dis*. 2015;60(Suppl. 2):s122–128. Available at: http://cid.oxfordjournals.org/content/60/suppl_2/S122.full


11. URINARY TRACT INFECTIONS

CONTENTS
A. Key Points ................................................................. 1
B. Culture and Urinalysis ............................................... 2
C. Outpatient Treatment ............................................. 3
D. References .................................................................. 3
E. Recommended Procedure for Using Urinary Catheter (Indwelling Foley) for Collecting Urine for Culture ................................................................. 4

A. Key Points

*Bacterial presence in the genitourinary system is classified into three distinct areas:*

- **ASYMPTOMATIC BACTERIURIAX**
  - Asymptomatic patients with positive cultures have either asymptomatic bacteriuria or a contaminated urine specimen.
  - Cultured urine will often grow organisms in the absence of infection, since urine passes through tissue that is typically colonized with bacteria.

- **UNCOMPLICATED CYSTITIS AND PYELONEPHRITIS**
  - Uncomplicated urinary tract infection occurs in a patient who does not have an underlying condition that increases the risk of failing therapy. The infection can occur in the upper or lower urinary track.

- **CATHETER-ASSOCIATED URINARY TRACT INFECTION (CAUTI)**
  - Catheterized patients will become colonized within 48 hours of catheterization, this does not necessarily indicate infection requiring treatment.
  - CAUTI should be confirmed by the presence of bacteria and elevated white blood cells in the urinalysis, together with systemic signs of infection.
  - The CDC’s National Healthcare Safety Network recommends that the Foley catheter be changed prior to obtaining a culture, if the Foley has been in place for 14 days or longer. (See References.)
  - An in-depth discussion of CAUTI is outside the scope of this guidance, but antimicrobial therapy is generally adjuvant to non-pharmacologic intervention, including catheter removal and routine reevaluation of continued need for catheter use. Consult with an infection control nurse for more information.
B. Culture and Urinalysis

- Urine culture must always be interpreted in the context of a urinalysis and patient symptoms.
- Urine culture should be collected prior to the initiation of antibiotic therapy, and used to narrow the empiric antimicrobial regimen.
- **Women:** Urine culture is not required for the treatment of women with uncomplicated cystitis (i.e., absence of fever, flank pain, or other suspicion for pyelonephritis), unless the patient has recurrent urinary tract infections, is immunocompromised, or has other comorbid complications.
- **Men:** Culture is always warranted for the evaluation of men presenting with symptoms of cystitis.
- **Using indwelling catheters for urine cultures:**
  - Clinical staff should aseptically utilize the collection (sampling) port.
  - **Appropriate for:** Local findings suggestive of CAUTI, evaluation of sepsis without a clear source, prior to certain urologic procedures, early pregnancy.
  - **Not appropriate (due to concerns regarding urine quality) for:** Screening patients for infection, asymptomatic elderly patients, diabetics, or documenting clearing of bacteria.
- Providers should deliver samples within the timeframe as directed by the laboratory.

**Indicators of Infection on a Urinalysis**

- **Turbid/cloudy urine.** Only applies to non-catheterized patients.
- **Positive leukocyte esterase:** Indicates the presence of white blood cells in the urine.
- **Presence of >10 WBCs:** Upon microscopy, the presence of 10 WBCs per high-power field is equivalent to 100 cells/mm³ of urine, which is considered the upper limit of normal.
- **Positive nitrite test:** Indicates the presence of a nitrate-reducing microorganism such as *Escherichia coli* or any other member of the Enterobacteriaceae family.
- **Elevated pH (6.5–8):** May indicate the presence of organisms that produce the enzyme urease, which catalyzes the hydrolysis of urea into ammonia and carbon dioxide; some of these organisms include *Staphylococcus saprophyticus*, *Klebsiella pneumoniae*, and *Proteus* species.
- **Presence of ≥10⁵ colony forming units (CFU) of bacteria per milliliter of urine.**
  - Approximately one-third to one-half of young women with symptomatic lower urinary tract infections have less than 10⁵ CFU/ml of urine. Thus, the presence of ≥10⁵ CFU/ml should be considered in the context of the patient’s characteristics and signs and symptoms.
C. Outpatient Treatment

- **Asymptomatic bacteriuria should not be routinely treated, with two important exceptions:** (1) pregnant women and (2) patients scheduled for genitourinary surgical procedures.
- Empiric regimens should be guided by local resistance patterns when available.
- Antimicrobial regimens should be tailored based on Culture and Sensitivity (C&S) results.

**FIRST-LINE EMPIRIC REGIMENS FOR WOMEN**

- **Uncomplicated cystitis** (absence of fever, flank pain, or other suspicion for pyelonephritis):
  - Nitrofurantoin 100mg po bid for 5 days **OR**
  - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 3 days
- **Acute pyelonephritis** (obtain C&S prior to initiation):
  - Ciprofloxacin 500mg po bid for 7 days **OR**
  - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 14 days (with single loading dose of intravenous ceftriaxone or aminoglycoside if susceptibility is unknown)

**FIRST-LINE EMPIRIC REGIMENS FOR MEN**

- **Acute cystitis** (obtain C&S prior to initiation):
  - Ciprofloxacin 500mg po bid for 7 days **OR**
  - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 7 days
- **Acute pyelonephritis** (obtain C&S prior to initiation):
  - Ciprofloxacin 500mg po bid for 10–14 days
  - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 10–14 days
  - **A 14-day duration is recommended for patients presenting with fever because febrile UTI is often associated with prostatic involvement.**

D. References


  - **All BOP staff have free access to DynaMed publications through BOP’s subscription.**


Hooten TM, Gupta K. Acute uncomplicated cystitis and pyelonephritis in women. In: UpToDate, Calderwood SB, ed., Up to Date, Waltham, Massachusetts. (Accessed on October 26, 2017.) Available at: https://www.uptodate.com/contents/acute-uncomplicated-cystitis-and-pyelonephritis-in-women?source=search_result&search=pyelonephritis&selectedTitle=2~83


E. Recommended Procedure for Using Urinary Catheter (Indwelling Foley) for Collecting Urine for Culture

NOTE: Institutions may wish to adopt the following as a local procedure.

PRINCIPLES:

- Procedure: Collection of urine for culture from a patient with a urinary catheter optimally should be performed by using the catheter sampling port. Suboptimal collection and/or transport of urine can lead to a false-positive urine culture, resulting in a misdiagnosis of urinary tract infection and unnecessary treatment with antibiotics.

- Timing: Urine samples should be plated within 2 hours of collection unless specimens are refrigerated immediately (and plated within 24 hours) or kept in a preservative tube (and plated within 48 hours).

- 14-Day Indication: Patients with a suspected UTI and a Foley urinary catheter in place for 14 days or longer should have the Foley catheter replaced prior to collecting urine for culture and antimicrobial treatment. (This does not apply to supra-pubic catheters.)

Note: The 14-day indication for a Foley catheter change prior to obtaining urine culture is indicated in the National Healthcare Safety Network (NHSN) long term care UTI protocol and has been noted by Clinical Infectious Disease research (see Hooten, T., 2010 in References) to hasten resolution of symptoms and to reduce the risk of subsequent CA bacteriuria.

PROCEDURAL GUIDELINES:

1. **Equipment:**
   a. Alcohol or chlorhexidine (CHG) wipes
   b. Specimen C&S tube with preservative, specimen UA tube
   c. Sterile Luer-Lok™ access device package
   d. Biohazard bag, patient label, and lab slip
   e. Sharps container
   f. PPE, as appropriate (gloves, eye protection)

2. **Planning and Preparation:**
   a. Obtain order to change the urinary catheter from the provider if the catheter has been in 14 days or longer, or if it is unknown how long the catheter has been in.
   b. Change the urinary catheter per facility protocol or policy.
   c. Use Standard Precautions (see Infection Control manual).
   d. Explain the procedure to the patient.
   e. Check that the indwelling sample port will accept the Luer-Lok access device. (The Bard E-Z Lock Sampling Port accepts a Luer-Lok or slip tip syringe).
   f. Identify how the sample will get to lab to be plated in the appropriate amount of time.

3. **Collection Procedure:**

   **Preparation:**
   a. Identify the patient using two identifiers.
   b. Wash hands.
   c. Apply gloves and other PPE, as needed.
   d. Kink drainage tubing (approximately 12 inches) below the sampling port until urine is visible under the access site.
   e. Cleanse sampling port with alcohol or CHG; scrub for 15–20 seconds.
   f. Using aseptic technique, position the Luer-Lok access device over the center of the sampling port. Push it in, and rotate the access device clockwise onto the sampling port until it fits securely.

   **Urine Collection:**
   g. Center the C&S tube over the holder portion of the access device and push it in. Once the tube is adequately filled, remove the tube from the holder.
   h. Check that tube is filled to at least the minimum fill line (4ml of urine).
   i. Invert the tube 8–10 times.
   j. Repeat steps g–i with UA tube, if ordered.
   k. Remove access device by rotating it counterclockwise.
   l. Unclamp the drainage tube.
   m. Discard the Luer-Lok device immediately into sharps container.

   (continues on next page)
**Process Specimen:**

n. Label collection container(s) in front of patient with:
   1) Date/time of collection.
   2) Method of collection (and type of catheter).
   3) Note if patient is on antibiotic therapy.

o. Place specimen(s) in biohazard bag(s)

p. Remove gloves and wash hands.

q. Send specimen to lab—ideally within 15 minutes of collecting, but no later than 48 hours if in a preservative C&S tube; or no later than 24 hours if not in preservative, but immediately refrigerated; or within 2 hours post-collection if not refrigerated and not in preservative.

**4. Documentation:**

In the Bureau Electronic Medical Record (BEMR), NMOS, or clinical encounter (depending on institution policy):

a. Record the reason for specimen collection.

b. Document whether collected via Foley or suprapubic catheter.

c. Document if catheter was changed immediately prior to collection of specimen.

d. Note the appearance, odor, color, or any unusual characteristics of the urine.

**Sources for Section E:**


12. **Helicobacter pylori**

**Contents**

A. Key Points ................................................................................................................................................ 1  
B. Treatment ................................................................................................................................................ 2  
C. Culture and Sensitivities........................................................................................................................... 2  
D. References ............................................................................................................................................... 3  

**A. Key Points**

- *Helicobacter pylori* (*H. pylori*) is a common infection of the gastrointestinal (GI) tract affecting about one-third of the U.S. population. It has been associated with many conditions, including peptic ulcer disease (PUD), gastritis, and malignancy. The infection is usually acquired during childhood, and one of the most likely risk factors is having infected parents.

- *H. pylori* is a Gram-negative bacteria that colonizes the gastric epithelium and produces a pH-neutral envelope via urea-metabolism into ammonia and carbon dioxide.

- Testing and treating for *H. pylori* is indicated for all patients with active PUD or a history of PUD, for whom eradication therapy has not already been prescribed. Testing and treating may also be indicated under certain other circumstances on a case-by-case basis. A list of specific such scenarios is outside the scope of this guidance.

- Testing and treating for *H. pylori* may also be helpful in patients taking chronic NSAID therapy, and in patients who have dyspepsia without ulcer or GERD.

- If a patient is tested and found to have *H. pylori*, treatment should be given.

- Diagnosis can be made with a variety of testing methods (e.g., urea breath test, stool testing, antibody testing, and tissue sampling).

- Concern with increasing resistance to clarithromycin is growing; therefore, quadruple therapy without the use of clarithromycin is now recommended as *first-line treatment*.  

November 2017
B. Treatment

**FIRST-LINE TREATMENT: QUADRUPLE THERAPY**

*Duration is 10-14 days:*

- Omeprazole 20mg po bid
- Bismuth subsalicylate 524mg po qid
- Metronidazole 250mg po qid
- Doxycycline 100mg po bid

**ALTERNATIVE FIRST-LINE TREATMENT: TRIPLE THERAPY**

- *Triple therapy can be used if community H. pylori clarithromycin-resistance is known to be <15% and the patient has no previous history of macrolide exposure.***

*Duration of treatment is 14 days:*

- Amoxicillin 1000mg po bid
  - Substitute metronidazole 500mg po bid if the patient is penicillin-allergic.
- Clarithromycin 500mg po bid
- Omeprazole 20mg po bid

**ANTIBIOTIC RESISTANCE**

- Antimicrobial resistance in *H. pylori* is well-documented in the literature, particularly to metronidazole and clarithromycin, and rates do appear to be rising. For example, the clarithromycin resistance rate published by the CDC was 12.9%, based on data collected from 1998–2002. In a more recent study, resistance rates were found to be about 30% in the U.S., but varied between 23–46%, depending on region.
- The use of amoxicillin and tetracycline historically has been minimally affected by resistance.
- When re-treating (salvage therapy), the selected medications should be different from the agents used during the initial regimen, and consideration given to a bismuth-based, quadruple therapy regimen.

**C. Culture and Sensitivities (C&S)**

Culture-guided or PCR-guided therapy has been studied and may be useful in some cases such as in areas of known high-prevalence of resistance. However, evidence is currently lacking for universal use of these approaches.
D. References


  ➤ All BOP staff have free access to DynaMed publications through BOP’s subscription.


  ➤ Medscape allows free access, although you must create an account and log in.
A. Key Points

- Dental infection primarily involves pulpal and periodontal infections. Secondary infections—including those involving soft tissues, as well as sinus infections—pose special treatment challenges (see Wynn, 2015, under References).

- Penicillin VK is the preferred narrow spectrum antibiotic for first line treatment for simple dental infections, including those of pulpal origin; clindamycin is effective in individuals with a penicillin allergy.

- Complex infections or those of the soft tissue may require broad spectrum antibiotics, based on patient progress or test results.

- Metronidazole is a synthetic antibiotic that is effective against anaerobic bacteria. When prescribed, it should be used in combination with penicillin.

- Third generation cephalosporin antibiotics such as ceftriaxone are generally inappropriate for dental indications.
  - In the BOP, dental use of ceftriaxone requires Regional Chief Dentist approval.

- Antibiotics should only be used in select dental situations, such as acute periodontal conditions where drainage or debridement is impossible, local spread of an infection is a concern, or there is presence of systemic signs or symptoms of infection.
  - Antibiotic usage should not be a substitute for interventional procedures.

- Antibiotics are NOT routinely required after oral operative interventions.

B. Bacterial Resistance to Antibiotics

- Patients with an early state odontogenic infection who do not respond to penicillin VK within 24 to 36 hours, may be assumed to have resistance.

- Bacterial resistance to penicillins is predominantly a result of beta-lactamase production. As a result, providers should switch therapy to either clindamycin or amoxicillin/clavulanic acid.
C. Prophylaxis

- When indicated, antibiotic prophylaxis should cover viridans group streptococci and be given 30–60 minutes prior to all dental procedures involving manipulation of gingival tissue or the periapical region of teeth, or perforation of the oral mucosa.

- Prophylaxis is indicated to help prevent infective endocarditis (IE) in select patient populations. The American Dental Association (ADA) and the American Heart Association (AHA) recommend the use of prophylaxis to prevent IE in the following cardiac conditions:
  
  ▶ **NON-CONGENITAL:** Prosthetic cardiac valve, prosthetic material used in a cardiac valve repair, history of IE, cardiac transplant that develops cardiac valvulopathy.
  
  ▶ **CONGENITAL:** Unrepaired or incompletely repaired cyanotic congenital heart disease; during the first six months after a procedure to completely repair a congenital heart defect with prosthetic material or device; and repaired congenital heart defect with residual defect at the site or adjacent to the site, or a prosthetic patch or device.

- Prophylaxis for those with prosthetic joint replacements is controversial due to lack of evidence. A 2014 ADA expert panel stated that, in general, evidence DOES NOT support the use of prophylactic antibiotics prior to dental procedures to prevent prosthetic joint infections.

### Dental Prophylaxis for Bacterial Endocarditis Prevention in Adult Patients

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Route</th>
<th>Prophylactic Regimen (Administer one of the following medications 30–60 minutes before the procedure.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NOT ALLERGIC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>to Penicillins or Ampicillin</td>
<td>Oral</td>
<td>Amoxicillin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 grams</td>
</tr>
<tr>
<td></td>
<td>IM²</td>
<td>Ampicillin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 grams</td>
</tr>
<tr>
<td><strong>ALLERGIC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>to Penicillins or Ampicillin</td>
<td>Oral</td>
<td>Cephalexin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 grams</td>
</tr>
<tr>
<td></td>
<td>Clindamycin</td>
<td>600 milligrams</td>
</tr>
<tr>
<td></td>
<td>Azithromycin or clarithromycin</td>
<td>500 milligrams</td>
</tr>
<tr>
<td></td>
<td>IM²</td>
<td>Cefazolin or ceftriaxone²,³</td>
</tr>
<tr>
<td></td>
<td>Clindamycin</td>
<td>600 milligrams</td>
</tr>
</tbody>
</table>

1. IM = Intramuscular (use if patient is unable to take oral medication).
2. Cephalosporins should NOT be used in persons with a history of anaphylaxis, angioedema, or urticaria from use of penicillins or ampicillin.
3. Broad spectrum antibiotics such as ceftriaxone are generally inappropriate for dental indications. In the BOP, dental use of ceftriaxone requires Regional Chief Dentist approval.

Adapted from:
Table 5 in Wilson, et al. *Prevention of Infective Endocarditis: Guidelines from the American Heart Association.* See References on next page.
D. References

- American Dental Association, Endodontics: A quarterly newsletter on dental specialties. Available at: http://www.ada.org/sitecore/content/home-ada/publications/jada/jada-specialty-scans/endodontics/endodontics_020317#one


14. SURGICAL SITE INFECTION PROPHYLAXIS

CONTENTS
A. Key Points ................................................................................................................................................ 1
B. Common Surgical Pathogens ................................................................................................................... 1
C. References ............................................................................................................................................... 1

A. Key Points

• The majority of surgical procedures for BOP inmates occur at outside hospital facilities, and prophylactic regimens and routines of the outside facility should be followed to prevent infections. Recommendations that do not follow current, evidence-based practices should be discussed with an Antimicrobial Stewardship Pharmacist and/or your Regional Medical Director.

• *Staphylococcus aureus* is the most common pathogen causing surgical site infection (SSI). The universal use of intranasal mupirocin is discouraged; however, pre-operative use in specific settings (e.g., gastrointestinal, orthopedic procedures) may be indicated. The data are most compelling in cardiac and orthopedic surgery patients.

• Pre-operative use of agents such as chlorhexidine should be used in accordance with outside hospital recommendation with a non-formulary submission.

B. Common Surgical Pathogens

• *Skin and soft tissue infections (SSTIs)* after clean procedures are predominately caused by normal skin flora:
  ➢ *Staphylococcus aureus*
  ➢ Coagulase-negative staphylococci

• The predominate organism after clean-contaminated procedures (abdominal procedures; heart, kidney, and liver transplants) are Gram-negative rods and enterococci, in addition to skin flora.

C. References